Cellumed (049180) Stock Overview

Cellumed Co., Ltd., a medical device biotechnology company, provides bone graft materials, implants, growth factors, and healthcare in Korea. It offers allograft products, which include achilles tendon, patellar tendon, and tibialis tendon that are used to reconstruct anterior and posterior cruciate ligaments; bone powder/chip that comprise DBM powder, cancellous bone coarse, and cancellous bone cube for the purpose of filling bone defects; and meniscus, a material used to reconstruct the meniscus between the knee joints in case of damage due to accidents, etc. The company also provides biologics comprising Rafugen DBM Gel Pro used for bone regeneration; bio meniscus graft, a supplement for meniscal cartilage; Bio BMP2, a bone graft material containing bone formation-inducing protein; Intergraft, a bone graft material for bone regeneration; and viscoseal syringe that temporarily replaces lost synovial fluid and helps in restoration of joint function. Additionally, the company offers joint replacement products comprising luminus flex total knee system and suminus flex patient-specific Instrument system, as well as engaged in cosmeceutical business. The company was formerly known as Korea Bone Bank Co., Ltd. and changed its name to Cellumed Co., Ltd. The company was founded in 1997 and is based in Seoul, South Korea.